OssDsign publishes Annual Report 2022

OssDsign AB (publ) announces that the Annual Report for 2022 is now available as a PDF on the company's website www.ossdsign.com. A PDF version is also attached to this press release.

“2022 was focused on continued execution of our growth strategy, ASCENT25. As we summarize the year, we delivered on key promises in the strategy, and became a stronger company with greater scalability. Despite challenging market conditions, we have shown record sales, three consecutive triple-digit growth quarters in the U.S., all-time high sales on Cranial PSI, and a very strong first full year on OssDsign Catalyst, confirming the transformative potential of our nanosynthetic bone graft for OssDsign.” said Morten Henneveld, CEO, OssDsign.

For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se

About OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give patients back the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.

Tags: